Change in Directors or Principal Officers Hope this doesn't have any adverse affect. I wonder why he's resigning?
Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
(b) On September 29, 2004, Christoph H. Westphal, M.D., Ph.D., a director of Alnylam Pharmaceuticals, Inc. ("Alnylam"), informed Alnylam that he was resigning from the board of directors of Alnylam effective October 14, 2004.
I think the intelectual patent issues may turn out to be somewhat messy, if only because this field became so hot so fast. Some of the early patents may be too broad or weren't not written with sufficient care. This is just a guess however.
Also, many companies will eventullay have to license patents from ALNY and others. For example:
>>Monday February 2, 8:08 am ET
BOTHELL, Wash., Feb. 2 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK - News), a leader in drug delivery technology, announced today that it has received a world-wide, non-exclusive license to the Fire et al. PATENTs and PATENT applications titled "Genetic Inhibition by Double-Stranded RNA" (including U.S. PATENT # 6,506,559 B1) from the Carnegie Institute of Washington, D.C. Under this license, Nastech plans to use the small interfering RNA (siRNA) technology in tight junction research and to develop therapeutics based upon siRNA technology. As the seminal description of RNA interference (RNAI), these PATENTs are considered fundamental to the field, as they broadly cover processes for introducing small interfering RNA into cells to control gene expression. <<